*originally published 12-14-22

Specialty pharma companies like Medexus (MDP.T) provides the upside potential of traditional drug development without the inherent risk attached to bringing a drug candidate to market from scratch.

The Canadian company brings already approved drugs from other jurisdictions and makes them available in the Canadian and American markets. Medexus is already generating substantial revenues from an existing drug portfolio which continues to grow market share. Cheaply valued compared to money coming in through the door, Medexus offers a immediate and substantial investment growth story. Who knows what the potential will increase to with the addition of new drugs like treosulfan?

Equity Guru’s content creators talk about the company, its portfolio, growing revenues and investment potential.

Enjoy!